KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash & Equivalents (2016 - 2025)

Boston Scientific's Cash & Equivalents history spans 17 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 374.64% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, up 374.64%, while the annual FY2025 figure was $2.0 billion, 374.64% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $2.0 billion at Boston Scientific, up from $1.3 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.1 billion in Q2 2024 and bottomed at $123.0 million in Q3 2023.
  • The 5-year median for Cash & Equivalents is $814.0 million (2023), against an average of $1.2 billion.
  • The largest annual shift saw Cash & Equivalents tumbled 93.21% in 2021 before it soared 2053.66% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $2.2 billion in 2021, then crashed by 48.06% to $1.1 billion in 2022, then decreased by 23.18% to $865.0 million in 2023, then tumbled by 52.14% to $414.0 million in 2024, then surged by 374.64% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Cash & Equivalents are $2.0 billion (Q4 2025), $1.3 billion (Q3 2025), and $741.0 million (Q2 2025).